Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

  • Technology appraisal guidance
  • TA322
  • Published: 
  • Last updated: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Kleijnen Systematic Reviews Ltd:

  • Riemsma R, Al M, Blommestein H, Deshpande S, Ryder S, Worthy G, Noake C, Armstrong N, Severens JL, Kleijnen J. Lenalidomide for the treatment of myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality: a Single Technology Appraisal. York: Kleijnen Systematic Reviews Ltd, 2013

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

  1. I. Company/sponsor:

    • Celgene UK

  2. II. Professional/specialist and patient/carer groups:

    • Royal College of Nursing

    • Royal College of Physicians

    • Royal College of Pathologists

    • The British Society for Haematology

    • MDS UK Support Group

    • Rarer Cancer Foundation

    • Leukaemia Care

  3. III. Other consultees:

    • None

  4. IV. Commentator organisations (did not provide written evidence and without the right of appeal):

    • National Collaborating Centre for Cancer

C. The following individuals were selected from clinical specialist and patient expert nominations from the non‑company/sponsor consultees and commentators. They gave their expert personal view on lenalidomide for treating myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • None

D. Representatives from the following company/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Celgene